ERBB2 and non-small cell lung carcinoma: both the DESTINY-Lung01 (NCT03505710) (53) and DESTINY-Lung02 (NCT04644237) trials demonstrated a higher OR for DS-8201a in patients with HER2-positive non-small cell lung cancer (NSCLC).